TEVATeva Pharmaceutical Industries Limited
$41.07+124% 1Y
$41.07
$18.3452 weeks$41.07
Latest close: a new 52-week highOct 9, 2026what changed →
The financials
Teva Pharmaceutical Industries Limited by the numbers
Teva Pharmaceutical Industries Limited (TEVA) reported revenue of $4.14B in Q2 2026 (quarter ended Jun 30, 2026), down 0.8% from the same quarter a year earlier. That came with a gross margin of 52% and net loss of $576M. For the full year FY2025, revenue was $17.3B (+4.3% year on year) and net income $1.41B. Its largest product in Q2 2026 was Austedo at $676M, 38% of the disclosed total, just ahead of Generics Medicians Including Otc And Biosimilars at 37%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $4.14B | $4.18B | −0.8% |
| Gross profit | $2.15B | $2.10B | +2.4% |
| Operating income | −$231M | $455M | to a loss |
| Net income | −$576M | $282M | to a loss |
| Diluted EPS | −$0.49 | $0.24 | to a loss |
| Product | Revenue | Share |
|---|---|---|
| Austedo | $676M | 38% |
| Generics Medicians Including Otc And Biosimilars | $660M | 37% |
| Ajovy | $116M | 6.5% |
| Other Products | $84M | 4.7% |
| Uzedy | $77M | 4.3% |
| COPAXONE | $61M | 3.4% |
| Respiratory Product | $58M | 3.3% |
| Bendeka And Treanda | $28M | 1.6% |
| License | $17M | 1.0% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $1.76B (+7.7%)
Ajovy grew +84% year on yearProduct And Service Other -1050% year on year
Segment Latestquarter on quarteryear on year
- Austedo$676.0M$676.0Mquarter on quarter +21%year on year +37%+21%+37%
- Generics Medicians Including Otc And Biosimilars$660.0M$660.0Mquarter on quarter +7.8%year on year -31%+7.8%-31%
- Ajovy$116.0M$116.0Mquarter on quarter +33%year on year +84%+33%+84%
- Other Products$84.0M$84.0Mquarter on quarter -32%year on year -24%-32%-24%
- Uzedy$77.0M$77.0Mquarter on quarter +22%year on year +43%+22%+43%
- COPAXONE$61.0M$61.0Mquarter on quarter -1.6%year on year -1.6%-1.6%-1.6%
- Respiratory Product$58.0M$58.0Mquarter on quarter -1.7%year on year +5.5%-1.7%+5.5%
- Bendeka And Treanda$28.0M$28.0Mquarter on quarter +3.7%year on year -30%+3.7%-30%
- License$17.0M$17.0Mquarter on quarter -19%year on year -41%-19%-41%
- Distribution Service$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
- Product And Service Other−$19.0M−$19.0Mquarter on quarter -195%year on year -1050%-195%-1050%
Drug Manufacturers, Specialty & Generic
Ranks #14 of 41 by RyuScore